Skip to main content
TipRanks
Go Ultimate75% OFF

OSE Immunotherapeutics SA (0RAD) Share Price & Analysis

2 Followers

0RAD Stock Chart & Stats

€1.62-€0.07(-4.08%)
At close: 4:30 PM GMT
€1.5€2€2.5€3Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 1.62 - EUR 1.65
52-Week Range
EUR 1.62 - EUR 5.88
Previous Close
EUR 1.69
Volume
N/A
Average Volume (3M)
3,254
Market Cap
EUR 38.40M
Enterprise Value
EUR 128.21M
Total Cash (Recent Filing)
EUR 22.65M
Total Debt (Recent Filing)
EUR 35.38M
Price to Earnings (P/E)
―
Beta
1.93
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Immunotherapy Focus

A focused presence in oncology and immune-inflammatory diseases gives OSE a coherent therapeutic identity and concentrates resources on areas where immune-system modulation is clinically relevant. This specialization can support deeper expertise and clearer development priorities over the coming quarters.

Multiple Development Platforms

The company is advancing more than one immunotherapy modality across preclinical and clinical stages, creating several potential routes to future value creation. A diversified development portfolio can reduce reliance on a single scientific approach, although outcomes remain dependent on successful advancement.

Improved Leverage Versus 2023

Although current leverage remains meaningful, improvement from the more leveraged 2023 position indicates some progress in balance-sheet structure. This provides a more favorable starting point for managing development spending and future financing needs than the earlier capital position.

Bears Say

Revenue Collapse And Heavy Losses

The sharp contraction in revenue and large 2025 net loss show that recent financial performance is highly unstable rather than steadily scaling. A very small revenue base limits internally generated funding, while continuing losses could weaken the company’s ability to sustain development without additional capital.

Significant Cash Burn

The reversal from strong positive cash generation to substantial operating and free-cash-flow burn materially increases funding dependency. Persistent cash outflows would reduce financial flexibility, potentially forcing OSE to seek financing or adjust development priorities while advancing its pipeline.

Leverage And Equity Erosion

Debt exceeding equity leaves the company with limited balance-sheet cushion relative to its obligations, and the decline in equity shows that losses are eroding capital. If weak profitability persists, leverage may constrain investment capacity and increase the consequences of future funding requirements.

OSE Immunotherapeutics SA News

0RAD FAQ

What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest share price was €1.62 and its highest was €5.88 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €38.40M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report. Following the earnings report the stock price went up 5.448%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in GB:0RAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology